MLTX Stock: Price, Earnings History and SEC Filings
MoonLake Immunotherapeutics (MLTX) last traded at $11.78, down 6.28% on the latest session and up 0.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.84 against an analyst estimate of $-0.90, a beat of 6.7%.
$11.78 -6.28%
1 month+0.68%
52-week high$23.29
52-week low$9.46
Volume1.13M
ExchangeNasdaqCM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
MLTX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 10, 2026 | $-0.84 | $-0.90 | +6.67% |
| Mar 2026 | May 11, 2026 | $-0.98 | $-0.91 | -7.69% |
| Dec 2025 | Feb 25, 2026 | $-0.92 | $-0.92 | +0.00% |
| Sep 2025 | Nov 5, 2025 | $-1.10 | $-0.89 | -23.60% |
MLTX beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for MLTX
SEC filing data is not available right now. You can search for MLTX on SEC EDGAR.
MLTX news
- MoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View HoldsOct 25, 2026 · finance.yahoo.com
- MoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet QuestionsOct 25, 2026 · finance.yahoo.com
- AbbVie Slips Behind Rivals as Lutikizumab Hits 31.4% Response in HS TrialOct 22, 2026 · tikr.com
- MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”Oct 22, 2026 · tikr.com
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (MLTX) is a US-listed public company on Nasdaq.